Journal
INFECTION AND IMMUNITY
Volume 68, Issue 6, Pages 3164-3171Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/IAI.68.6.3164-3171.2000
Keywords
-
Categories
Funding
- NIAID NIH HHS [R29 AI-33656, R01 AI033656-06A2, R01 AI033656, R29 AI033656] Funding Source: Medline
Ask authors/readers for more resources
Malaria merozoites require the presence of specific surface receptors on the red blood cell for invasion. Plasmodium vivax, requires the Duffy blood group antigen as an obligate receptor for invasion, The parasite Duffy binding protein (DBP) is the ligand involved in this process, making the DBP a potential vaccine candidate. A preliminary objective was to study whether people exposed to vivax: malaria acquire antibodies that have the ability to block erythrocyte cytoadherence to the PvDBP, In comparison, we studied the immunogenicity of various recombinant DBP vaccines and investigated their potential to induct antifunctional antibodies. In order to do so, recombinant proteins to different regions of the putative ectodomain of the DBP and a DNA vaccine were used to immunize laboratory animals. An in vitro cytoadherence assay was used to investigate the presence of antifunctional antibodies in plasmas from people naturally exposed to vivax malaria, as well as in antisera obtained by animal vaccination, Our results showed that human plasma from populations naturally exposed to vivax malaria, as well as antisera obtained by vaccination using recombinant proteins, a DNA vaccine, and a synthetic peptide to DBP, inhibited in vitro binding of human erythrocytes to the DBP ligand domain (DBPII) in correlation to their previously measured antibody titer, Our results provide further evidence for the vaccine potential of this essential parasite adhesion molecule.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available